Caroline Besson1,2, Nicolas Noel3, Remi Lancar4, Sophie Prevot5, Michele Algarte-Genin6, Eric Rosenthal6, Fabrice Bonnet7, Marie-Caroline Meyohas8, Marialuisa Partisani9, Lucie Oberic10, Jean Gabarre11, Cécile Goujard3, Antoine Cheret12, Cedric Arvieux13, Christine Katlama14, Dominique Salmon15, François Boué16, Regis Costello17, Houria Hendel-Chavez18, Yassine Taoufik18, Hélène Fontaine19, Paul Coppo20, Nicolas Mounier21, Pierre Delobel22, Dominique Costagliola4. 1. Hematology-Oncology Unit, Centre Hospitalier de Versailles, Le Chesnay. 2. Université Versailles Saint Quentin en Yvelines, Université Paris-Saclay, Communauté Paris-Saclay; Centre for Research in Epidemiology and Population Health (CESP) INSERM Unit 1018, Villejuif. 3. INSERM U1184, Centre for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin-Bicêtre; Université Paris Sud, Faculté de médecine Paris Sud, Le Kremlin-Bicêtre, AP-HP, Hôpitaux Paris Sud, Internal Medicine Unit, Le Kremlin-Bicêtre. 4. Sorbonne Universités, INSERM, UPMC Université Paris 06, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS1136), Paris. 5. AP-HP, Hôpitaux Paris Sud Site Béclère, Pathology Unit, Clamart. 6. Internal medicine unit, CHU l'Archet, Nice. 7. CHU Bordeaux, Internal Medicine and Infectious Diseases Unit, and INSERM U1219, Université de Bordeaux, Bordeaux. 8. AP-HP CHU Saint-Antoine, Infectious Diseases Unit, Paris. 9. Hôpitaux Universitaires, HIV Infection Unit, Strasbourg. 10. Toulouse III Paul Sabatier University, U1037, CRCT, Department of Haematology, Institut Universitaire du Cancer (IUC), Toulouse. 11. AP-HP CHU Pitié-Salpêtrière, Department of Haematology, Paris. 12. Infectious diseases Unit, Hôpital de Tourcoing, Tourcoing. 13. Infectious Diseases Unit, CHU de Rennes, Rennes. 14. Infectious Diseases Unit, Hôpital La Pitié-Salpêtrière. 15. Infectious Diseases Unit, Hôpital Cochin, Paris. 16. Université Paris Sud, Faculté de médecine Paris Sud, Le Kremlin-Bicêtre, AP-HP, Hôpitaux Paris Sud Site Béclère, Clinical Immunology Unit, Clamart. 17. Department of Hematology, AP-HM, Assistance Publique Hôpitaux de Marseille, Marseille. 18. INSERM U1184, Centre for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin-Bicêtre, Université Paris Sud, Faculté de médecine Paris Sud, Le Kremlin-Bicêtre; AP-HP, Hôpitaux Paris Sud, Immunology Unit, Le Kremlin-Bicêtre. 19. Hepatology unit, Hôpital Cochin. 20. Department of Hematology, AP-HP CHU Saint-Antoine, Paris. 21. Department of Onco-Hematology, Archet Hospital, Nice. 22. Infectious Diseases Unit, CHU Toulouse, Toulouse, France.
Abstract
OBJECTIVE: Chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infections are associated with increased risks of lymphomas in the non-HIV setting. Their impacts on HIV-associated lymphomas deserved further studies in the modern combined antiretroviral therapy (cART) era. DESIGN: We evaluated the associations between HCV, HBV and HIV-related lymphomas in the Lymphovir-ANRS-CO16 cohort. METHODS: Prevalence of HCV seropositivity and chronic HBV infections were compared with those observed in the French Hospital Database on HIV (FHDH-ANRS-CO4). RESULTS: Between 2008 and 2015, 179 patients with HIV-related lymphomas from 32 French hospitals were enrolled, 69 had Hodgkin's lymphoma (39%), and 110 non-Hodgkin's lymphoma (NHL) (61%). The prevalence of HCV infection was higher in patients with NHL than in the FHDH-ANRS-CO4 [26 versus 14%, odd ratio (OR): 2.15; 95% confidence interval (1.35-3.32)] whereas there was no association between Hodgkin's lymphoma and chronic HCV infection. Chronic HBV infection was not associated with NHL in our cohort with a prevalence of 5 versus 7% in FHDH-ANRS-CO4 but tended to be associated with Hodgkin's lymphoma [prevalence of 14%, OR: 2.16 (0.98-4.27)]. Chronic HCV infection tended to pejoratively impact 2-year overall survival in patients with NHL: 72% [57%, 91%] versus 82% [74%, 91%], hazard ratio: 2.14 [0.95-4.84]. In contrast, chronic HBV infection did not correlate with outcome. CONCLUSION: In the modern cART era, chronic HCV infection is associated with an increased risk of NHL in PLWHIV and tends to pejoratively impact overall survival. HBV infection is not associated with the risk of NHL but with a borderline increase of Hodgkin's lymphoma risk.
OBJECTIVE:Chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infections are associated with increased risks of lymphomas in the non-HIV setting. Their impacts on HIV-associated lymphomas deserved further studies in the modern combined antiretroviral therapy (cART) era. DESIGN: We evaluated the associations between HCV, HBV and HIV-related lymphomas in the Lymphovir-ANRS-CO16 cohort. METHODS: Prevalence of HCV seropositivity and chronic HBV infections were compared with those observed in the French Hospital Database on HIV (FHDH-ANRS-CO4). RESULTS: Between 2008 and 2015, 179 patients with HIV-related lymphomas from 32 French hospitals were enrolled, 69 had Hodgkin's lymphoma (39%), and 110 non-Hodgkin's lymphoma (NHL) (61%). The prevalence of HCV infection was higher in patients with NHL than in the FHDH-ANRS-CO4 [26 versus 14%, odd ratio (OR): 2.15; 95% confidence interval (1.35-3.32)] whereas there was no association between Hodgkin's lymphoma and chronic HCV infection. Chronic HBV infection was not associated with NHL in our cohort with a prevalence of 5 versus 7% in FHDH-ANRS-CO4 but tended to be associated with Hodgkin's lymphoma [prevalence of 14%, OR: 2.16 (0.98-4.27)]. Chronic HCV infection tended to pejoratively impact 2-year overall survival in patients with NHL: 72% [57%, 91%] versus 82% [74%, 91%], hazard ratio: 2.14 [0.95-4.84]. In contrast, chronic HBV infection did not correlate with outcome. CONCLUSION: In the modern cART era, chronic HCV infection is associated with an increased risk of NHL in PLWHIV and tends to pejoratively impact overall survival. HBV infection is not associated with the risk of NHL but with a borderline increase of Hodgkin's lymphoma risk.